Intestinal Microbiota Articles & Analysis
10 news found
MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the exclusive right to use MV Bio ...
” said Adam Matson, MD (Connecticut Children’s Medical Center and Assistant Professor of Pediatrics and Immunology at UConn Health) “This exciting new approach represents a major technical advancement in the classification of intestinal microbiota and will enable source-tracking of pathogenic and beneficial microbes in the ...
The presentation has been included in the morning stream titled “Introducing the Era of Engineered Microbes” the 29th at 11.35. Leveraging Gut Microbiota Cross-Talk with Immune System to Enhance Cancer Immunotherapy Extracellular ATP (eATP) as a bacterial metabolite in host-microbiota mutualism Adaptive modulation of intestinal ...
The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator in cancer and beneficial for the ...
MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies. “We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global ...
The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator in cancer and beneficial for the ...
The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: ApyraVax with the lead indication of Clostridioides difficile infection ApyraMed with lead indications as immune modulator in cancer and beneficial for the ...
“The technology platform the company is based on is the result of a surprising development of the research work carried out in my lab at the IRB that progressed from studies on the cell biology of T cells to the discovery of a crucial mechanism regulating the mutualism between our organism and the intestinal microbiota. I would like also to mention the ...
The objective of the meetings was to explore and better understand the main functions of the gut, the key role of intestinal microbiota, and the influence of a probiotic solution, LEVUCELL® SB (Saccharomyces cerevisiae var. boulardii CNCM I-1079). ...
Work on intestinal microbiota carried out at INRA for more than 30 years has, with the recent development of metagenomics, led to new breakthroughs that have transformed our understanding of the ecosystem of the human digestive tract. ...